LOS ANGELES, Dec. 1, 2015 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) announced today the establishment of an agreement with the European Organisation for Research and Treatment of Cancer (EORTC) for the phase 3 registrational trial of ICT-107 in patients with newly diagnosed glioblastoma (GBM). The EORTC contributed to the trial design and will assist ImmunoCellular Therapeutics in facilitating accrual of patients for this trial in Europe.
Prof. Michael Weller of the University Hospital Zurich, Chair of the EORTC Brain Tumor Group, and coordinator of this study commented "The EORTC is a leader in enabling multi-disciplinary approaches to investigate strategic therapeutic questions through clinical and translational research. We aim to improve the understanding of disease and help advance innovative therapies in cancer care for the benefit of patients. We are pleased to collaborate with ImmunoCellular to conduct the phase 3 registrational trial of ICT-107, a potentially promising cancer immunotherapeutic approach to treating brain cancer."
"Working with the EORTC is a key step in our strategy to establish a network of relationships within the clinical oncology community to support the conduct of the ICT-107 Phase 3 trial," said Andrew Gengos, ImmunoCellular's Chief Executive Officer. "For several months, we have been working with prominent cancer cooperative groups in the US and Europe to refine and finalize the trial design, gain their endorsement and secure their help in executing a high quality trial. With EORTC's support, we believe that we can access large numbers of affiliated trial sites which will facilitate patient accrual. We anticipate patient enrollment in the phase 3 trial to begin within the next few weeks."
About ImmunoCellular Therapeutics, Ltd.
ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The phase 3 registrational trial of lead product candidate, ICT-107, a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells, is open for patient enrollment. ImmunoCellular's pipeline also includes: ICT-121, a dendritic cell immunotherapy targeting the CD133 antigen on stem cells in recurrent glioblastoma; ICT-140, a dendritic cell immunotherapy targeting antigens on ovarian cancer stem cells; and the Stem-to-T-cell research program which engineers the patient's hematopoietic stem cells to generate antigen-specific cancer-killing T cells.
Forward-Looking Statements for ImmunoCellular Therapeutics
This press release contains certain forward-looking statements that are subject to a number of risks and uncertainties, including the risk that ICT-107 can be further successfully developed or commercialized and the timing of accrual of patients and completion of the trial. Additional risks and uncertainties are described in IMUC's most recently filed quarterly report on Form 10-Q and annual report on Form 10-K. Except as permitted by law, IMUC undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
ImmunoCellular Therapeutics, Ltd.
SOURCE ImmunoCellular Therapeutics, Ltd.